Each quarter, Locust Walk’s deal team compiles key statistics and trends on strategic transactions and financings. Our 2022 Third Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 Second Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape.
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2022 First Quarter Report applies the latest data to analyze current activities in the life sciences deal landscape. In this report you can find...
The CAR-T and oncology cell therapy landscape has broadly seen significant continued development, with over 2,000 therapies in development and ~1,350 active trials globally
Induced pluripotent stem cell (iPSC) technology has the potential to transform the treatment landscape and bring curative options to patients. iPSC-derived cells have the potential to address a wide range of diseases and serve as a fertile ground for new investment...
Each quarter, Locust Walk deal team members compile key statistics and trends on strategic transactions and financings. Our 2021 Year End Report applies the latest data to analyze current activities in the life sciences deal landscape.
